Two Liberian hospitals deploy germ-killing robots to combat Ebola virus

18 August 2014 (Last Updated August 18th, 2014 18:30)

Liberia-based JFK Hospital and ELWA Hospital have deployed two five-foot superbug-slaying machines (devices) from the US in order to combat Ebola virus outbreak.

Ebola virus virion

Liberia-based JFK Hospital and ELWA Hospital have deployed two five-foot superbug-slaying machines (devices) from the US in order to combat Ebola virus outbreak.

Dubbed TRU-D SmartUVC, the new device will help in disinfecting healthcare environments where Ebola patients are being treated.

TRU-D is the only portable UV disinfection device that features Sensor360 technology to calculate the time needed to react to room variables, including size, geometry, surface reflectivity and the amount and location of equipment in the room.

The device effectively delivers a lethal dose of UV-C light during a single cycle from a single, central location in the room and works by generating UV light energy that modifies the DNA structure of viral pathogens, such as Ebola, so that they cannot reproduce.

Viruses that cannot reproduce cannot colonise and harm patients, while the device has been validated by more than ten studies to be 99.99% effective in reducing the most common pathogens that cause healthcare-associated infections.

TRU-D inventor and a fellow in the Royal Society of Tropical Medicine and Hygiene Dr Jeffery Deal said: "We developed TRU-D SmartUVC technology to combat the devastating effects of hospital acquired infections.

"Unlike many diseases, Ebola strikes hospital workers more than any other group, making it the ultimate hospital-acquired infection."

"We developed TRU-D SmartUVC technology to combat the devastating effects of hospital acquired infections."

Symptoms of Ebola virus disease include fever, headache, weakness, achiness, diarrhoea, vomiting, stomach pain, lack of appetite and abdominal bleeding.

The healthcare providers in the US, Canada, the UK and Saudi Arabia are using TRU-D to reduce pathogens, such as Ebola, Middle East Respiratory Syndrome (MERS), influenza, norovirus, Clostridium difficile, Methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE).

TRU-D SmartUVC president and CEO Chuck Dunn said: "We know through extensive CDC-funded research specific to TRU-D conducted by thought-leaders in epidemiology and infection prevention that TRU-D is effective at eliminating any pathogen by delivering a precisely measured UVC dose.

"As soon as we knew we could aid struggling hospitals in Liberia, our team came together and formulated a plan to get TRU-D on the ground.

"With the help of the Liberian Government and Dr Deal's on-the-ground expertise, we know TRU-D is going to make an impact at JFK and ELWA Hospitals."


Image: Ebola virus virion. Photo: courtesy of CDC / Cynthia Goldsmith.